Full Text Full Text (PDF) Correction (v163,p1843) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Wagner, K. D. Articles by Linden, D. Search for Related Content PubMed Citation Articles by Wagner, K. D. Articles by Linden, D. Other Childhood Disorders Bipolar Disorder Anticonvulsants Related Articles

A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents

OBJECTIVE: This multicenter trial examined the efficacy and safety of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. METHOD: A total of 116 outpatients 7 to 18 years of age with bipolar I disorder, manic or mixed, were recruited at 20 centers in the United States and randomly assigned to receive 7 weeks of double-blinded, flexibly dosed treatment with oxcarbazepine (maximum dose 900–2400 mg/day) or placebo. The primary efficacy measure was the mean change from baseline to endpoint in the Young Mania Rating Scale (YMRS), using the last-observation-carried-forward method. RESULTS: Oxcarbazepine (mean dose=1515 mg/day) did not significantly improve YMRS scores at endpoint compared with placebo [adjusted mean change: oxcarbazepine, –10.90 (N=55); placebo, –9.79 (N=55)]. Dizziness, nausea, somnolence, diplopia, fatigue, and rash were each reported in at least 5% of the patients in the oxcarbazepine group with an incidence at least twice that of the placebo group. The majority of adverse events were mild to moderate and occurred during the titration period. Eleven patients (19%) in the oxcarbazepine group discontinued the study because of adverse events, compared with two (4%) in the placebo group. CONCLUSIONS: Oxcarbazepine is not significantly superior to placebo in the treatment of bipolar disorder in youths. While the overall adverse event profile was similar to that reported for patients with epilepsy, the incidence of psychiatric adverse events for both the oxcarbazepine and placebo groups was higher than that reported for the epilepsy population.

Related Articles:

Flying Almost Blind

Ellen Leibenluft
Am J Psychiatry 2006 163: 1129-1131. [Full Text] [PDF]

This article has been cited by other articles:

				J. M. McClellan Olanzapine and Pediatric Bipolar Disorder: Evidence for Efficacy and Safety Concerns Am J Psychiatry, October 1, 2007; 164(10): 1462 - 1464. [Full Text] [PDF]

				M. Tohen, L. Kryzhanovskaya, G. Carlson, M. DelBello, J. Wozniak, R. Kowatch, K. Wagner, R. Findling, D. Lin, C. Robertson-Plouch, et al. Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania Am J Psychiatry, October 1, 2007; 164(10): 1547 - 1556. [Abstract] [Full Text] [PDF]

				C. M MacMillan and J. M Gonzalez-Heydrich Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents Evid. Based Ment. Health, May 1, 2007; 10(2): 59 - 59. [Full Text] [PDF]

				What's Good for Geese May Not Be Good for Goslings: The Case of Oxcarbazepine Journal Watch Psychiatry, July 24, 2006; 2006(724): 1 - 1. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us